4/A: BioXcel Therapeutics Executive Corrects Stock Ownership Report, Zero Holdings Reported

Vincent O'Neill, an executive at BioXcel Therapeutics, filed an amended SEC Form 4 to correct a previous report that incorrectly stated he was granted restricted stock units and options, clarifying he holds no such securities.

Summary

• Vincent O'Neill, an Executive Vice President at BioXcel Therapeutics, filed an amendment to a previous SEC Form 4 filing.
• The amendment corrects an error in the original filing from March 16, 2023, which incorrectly reported an award of 9,000 restricted stock units (RSUs) and options to purchase 32,000 shares of BioXcel's common stock.
• The corrected filing clarifies that O'Neill was not granted these RSUs and options and does not beneficially own any shares underlying these awards.
• The filing indicates that O'Neill directly owns 3,158 shares of common stock.

Sentiment

Score: 4

Explanation: The document corrects a previous error, which is a negative signal, but it's a routine filing. The sentiment is neutral to slightly negative.

Negatives

• The original SEC filing contained incorrect information regarding stock awards to a BioXcel Therapeutics executive, requiring an amendment.

Risks

• Inaccurate reporting in SEC filings can lead to investor confusion and potential regulatory scrutiny.

Industry Context

SEC filings are a routine part of corporate governance and are used to ensure transparency in financial markets. Amendments are sometimes necessary to correct errors or omissions in previous filings.

Stakeholder Impact

• The correction of the SEC filing ensures that shareholders and potential investors have accurate information regarding executive stock ownership.

Key Dates

Keywords

SEC Form 4, Amendment, BioXcel Therapeutics, Stock Options, Restricted Stock Units, Vincent O'Neill, Ownership